Boswellia
Clinically Informed Overview
Last reviewed: September 2026
Boswellia at a Glance
What It Is
Boswellia is an extract derived from the gum resin of Boswellia serrata, a tree traditionally used in Ayurvedic medicine. Its best-studied natural compounds are called boswellic acids. One of these, 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), is present in several standardized extracts. Boswellia supplements are not interchangeable with frankincense essential oil.
Main Benefit
Research suggests that certain standardized Boswellia serrata extracts may support joint comfort, mobility, and physical function. The strongest clinical evidence involves adults with knee osteoarthritis; evidence for other joints and other pain conditions is substantially more limited.
What to Expect
The most clinically aligned dosing depends on the extract:
Aflapin®/AprèsFlex®: 100 mg once daily
5-LOXIN®: 100–250 mg once daily
Some formulation-specific trials reported improvement within 5–7 days, but this early response should not be assumed for every individual or product. A more practical evaluation period is 4–8 weeks of consistent daily use.
Boswellia is generally well tolerated. Reported adverse effects are usually mild and may include:
Nausea
Abdominal Discomfort
Heartburn or reflux
Diarrhea or constipation
Headache
Medication Caution
Laboratory data suggest that Boswellia may affect platelet activity and several drug-transport pathways. The clinical importance is uncertain, but individuals taking anticoagulant or antiplatelet medications, drugs with a narrow therapeutic range, or multiple prescription medications should consult a qualified healthcare professional before use.
The Verus Standard
Verus PhytoMed™ prioritizes formulation-specific clinical evidence, not the largest milligram number or a generic “boswellic acids” claim. Among currently available forms, Aflapin®/AprèsFlex® at 100 mg daily has the broadest formulation-specific clinical program, including randomized trials lasting 30, 90, and 180 days. 5-LOXIN® at 100–250 mg daily also has direct randomized-trial support and is standardized to 30% AKBA.
Conventional extracts standardized only to total boswellic acids have also been studied, but their composition, analytical methods, and dosing vary substantially. A label claim such as “65% boswellic acids” should not be assumed to provide the same clinical alignment as a named, trial-matched extract.
What You’ll Learn
Boswellia is a resin-derived botanical studied primarily for joint comfort and mobility. This overview summarizes:
What Boswellia is
How it is believed to work in the body
What current clinical research suggests
Which standardized extracts have the strongest evidence
Typical dosing used in studies
How to take it in practice
Safety considerations and limitations of the evidence
Evidence-aligned product selections
What Is Boswellia?
Boswellia refers to a genus of resin-producing trees found in India, North Africa, and the Middle East. Most oral clinical research has evaluated extracts from the gum resin of Boswellia serrata, also known as Indian frankincense, salai guggul, or shallaki.
The resin contains multiple pentacyclic triterpenes known as boswellic acids, including:
Beta-boswellic acid
Acetyl-beta-boswellic acid
11-keto-beta-boswellic acid (KBA)
3-O-acetyl-11-keto-beta-boswellic acid (AKBA)
AKBA is frequently emphasized because of its activity in laboratory models and because several proprietary extracts are standardized to a defined AKBA content. However, Boswellia extracts contain multiple constituents, and clinical activity cannot be attributed to AKBA alone with certainty.
Oral Boswellia extracts should not be confused with frankincense essential oil used for fragrance, topical application, or aromatherapy. Essential oils do not reproduce the boswellic-acid composition or clinical dosing used in oral joint studies.
How Boswellia Works
Boswellic acids may influence several pathways involved in inflammation. The best-known proposed mechanism involves 5-lipoxygenase (5-LOX), an enzyme that helps produce inflammatory compounds called leukotrienes. Laboratory studies suggest that AKBA can affect this enzyme, although it remains uncertain how much this mechanism contributes to the benefits observed in people. (Ref. 1)
Other laboratory and early human research suggests that Boswellia constituents may also affect:
Cellular signals that regulate inflammation
Inflammatory messenger proteins
Enzymes involved in connective-tissue breakdown
Oxidative stress
These findings provide possible explanations for the improvements in joint symptoms reported in some clinical trials. However, laboratory mechanisms do not establish that Boswellia treats inflammatory diseases or prevents cartilage loss or other structural joint damage.
Absorption and Metabolism
Only a limited and variable amount of some boswellic acids reaches the bloodstream after oral use. This is particularly true for KBA and AKBA. Human studies suggest that taking a conventional Boswellia extract with food, especially a meal containing fat, may increase absorption. (Ref. 2)
Several proprietary formulations have been designed to improve absorption. These include Aflapin®/AprèsFlex®, which combines a standardized gum-resin extract with an oil-rich portion of the resin, and phytosome preparations such as Casperome®, which combine the extract with phospholipids to help the body absorb it.
Greater absorption may allow some formulations to be used at lower doses. However, doses cannot be compared by milligrams alone. Clinical conclusions should be based on the specific extract and dose evaluated in human studies.
What the Research Shows
While many individual randomized trials report favorable results, systematic reviews have reached somewhat different conclusions because the studies use different extracts, doses, comparators, durations, and outcome scales.
Joint Comfort and Physical Function
Most human research on joint-related outcomes has enrolled adults diagnosed with knee osteoarthritis. In these trials, several standardized Boswellia extracts have been associated with improvements in knee discomfort, stiffness, walking ability, and physical function. Whether these findings apply to other joints or to people without osteoarthritis remains uncertain. (Refs. 3–15)
A 2014 Cochrane review found moderate-quality evidence that selected Boswellia preparations improved pain and physical function compared with placebo, although the evidence varied by preparation and comparison. (Ref. 13)
A 2018 systematic review and meta-analysis also reported favorable short-term pain and function outcomes for Boswellia, including large pooled effects. The limited number and size of the contributing studies mean these estimates should not be presented as the improvement an individual can expect. (Ref. 14)
A 2020 meta-analysis of seven randomized trials involving 545 participants found that Boswellia improved several measures of knee discomfort, stiffness, and physical function. (Ref. 4) However, the studies used different extracts and scoring systems, making it difficult to estimate how much improvement an individual should expect.
A 2024 meta-analysis reached a less certain overall conclusion. (Ref. 5) When studies using different comparison treatments were pooled, the analysis did not find a statistically significant overall effect, in part because the results varied substantially among studies. Analyses limited to placebo-controlled studies were more favorable. These findings illustrate how strongly the conclusions depend on the formulations, comparison groups, and outcomes included in the analysis.
A newer 90-day randomized, placebo-controlled trial of BOSMAX® enrolled 150 adults and reported improvements in knee pain, stiffness, and physical function. SF-36 quality-of-life scores did not improve significantly. These findings add evidence for the tested formulation but do not establish superiority over other extracts or long-term safety. (Ref. 15)
Research Summary: Taken together, the evidence suggests that selected standardized Boswellia extracts may support knee comfort and physical function in some adults. However, a precise expected effect size cannot be established. Favorable findings have been reported in formulation-specific randomized trials of Aflapin®/AprèsFlex® and 5-LOXIN®, but overall certainty remains limited by small studies, relatively short follow-up, substantial differences among studies, and frequent manufacturer involvement.
Onset and Duration of Effect
Several randomized trials of Aflapin®/AprèsFlex® 100 mg daily reported measurable improvements in some pain or function outcomes by day 5 or day 7. A trial of 5-LOXIN® reported early improvement by day 7 with the 250 mg dose. (Refs. 7–9)
These early findings come from relatively small formulation-sponsored studies. Boswellia is better viewed as a consistent daily supplement rather than an acute, as-needed option. Systematic-review authors have generally suggested at least four weeks of use before judging response, and many clinical trials lasted 8–12 weeks. (Refs. 4, 6-8, 11)
Other Support
Boswellia has also been studied for digestive, respiratory, and other musculoskeletal concerns. (Refs. 1, 16, 17)
Current evidence outside knee discomfort is considerably less established:
Small studies have evaluated inflammatory bowel conditions, but results are inconsistent and should not be interpreted as evidence of disease treatment.
A few small trials have evaluated respiratory symptoms, but the evidence is insufficient for firm conclusions.
Preliminary studies have examined back pain, tendon discomfort, and other musculoskeletal symptoms, often using combination products or uncontrolled designs.
There is not enough evidence to conclude that Boswellia protects cartilage or slows structural joint deterioration.
Findings from knee studies should not automatically be extrapolated to the hip, spine, shoulder, hands, or other joints.
Quality and Standardization
High-quality Boswellia supplements should clearly identify:
Boswellia serrata as the botanical species
Gum resin as the plant material
The named extract or extraction method
Standardization to AKBA and/or accurately measured boswellic acids
The amount of extract per capsule and daily serving
Testing for identity, potency, heavy metals, microbes, and other contaminants
Transparent manufacturing under current good manufacturing practices
The most clinically relevant extract forms include:
Aflapin®/AprèsFlex®
Enhanced-bioavailability Boswellia serrata gum-resin preparation
Standardized to 20% AKBA
Most commonly studied at 100 mg once daily
Supported by several randomized trials, including studies lasting up to 180 days
5-LOXIN®
AKBA-enriched Boswellia serrata gum-resin extract
Standardized to 30% AKBA
Studied at 100–250 mg once daily
Supported by randomized trials lasting up to 90 days
Boswellin® Super
Full-spectrum Boswellia serrata gum-resin extract standardized to 30% AKBA with other beta-boswellic acids
Studied in recent randomized trials, including doses of 150 or 300 mg twice daily
Promising, but the independent and commercially transferable evidence base is less established than for Aflapin®/AprèsFlex® and 5-LOXIN®
Conventional total-boswellic-acid extracts
Often labeled as containing 40–70% total boswellic acids
Commonly evaluated in older studies at approximately 300–500 mg two or three times daily
Less reliably interchangeable because analytical methods and individual boswellic-acid profiles may differ
Boswellia phytosome preparations
Designed to improve absorption using a phospholipid delivery system
Supported by pharmacokinetic and preliminary clinical research
Currently have less formulation-specific randomized evidence for knee outcomes than Aflapin®/AprèsFlex® or 5-LOXIN®
A higher percentage of “total boswellic acids” does not necessarily indicate a better or more evidence-aligned product. Some older percentage claims were derived from nonspecific testing methods that could overestimate true boswellic-acid content. Verus PhytoMed™ therefore gives greater weight to a clinically studied branded extract with transparent analytical standardization.
Typical Research Dosing
In clinical research settings, Boswellia dosing has depended on the specific formulation. The schedules below distinguish the amount taken per dose from the total daily amount.
Aflapin®/AprèsFlex®
100 mg total daily
The 30-day and 90-day trials administered 100 mg once daily. (Refs. 8, 9)
A longer trial evaluated 100 mg daily for 180 days. (Ref. 12)
5-LOXIN®
100 mg once daily or 250 mg once daily.
These regimens were evaluated for 90 days (Refs. 7, 8)
Boswellin® Super
150 mg twice daily or 300 mg twice daily, providing total daily doses of 300 mg or 600 mg, respectively, in a 90-day trial. (Ref. 11)
An earlier Boswellin® formulation was evaluated at approximately 169 mg twice daily for 120 days. (Ref. 10)
Conventional Boswellia extracts
One early trial evaluated 333 mg three times daily, providing approximately 1,000 mg daily, during eight-week treatment periods. (Ref. 6)
Conventional extracts vary in composition and standardization; this regimen should not be assumed to apply to every product.
These dosing ranges reflect research protocols used in clinical studies. The labeled milligram amounts of different extracts are not directly interchangeable, and no universally accepted equivalent dose has been established.
Consult a qualified healthcare professional before using any dietary supplement.
How to Take It
Select one clearly standardized extract rather than combining multiple Boswellia products.
Match the daily amount to the extract-specific dose used in research whenever possible.
Take Boswellia with a meal. This may improve gastrointestinal tolerance and can increase absorption of boswellic acids from conventional extracts.
Use it consistently each day rather than only when discomfort occurs.
Although some studies reported changes within 5–7 days, allow approximately 4–8 weeks to evaluate an individual response.
If there is no meaningful improvement after an adequate trial, continued use may offer limited practical value.
Do not exceed the product label or use Boswellia to replace prescribed therapy without discussing it with a qualified healthcare professional.
Safety and Tolerability
Boswellia has been generally well tolerated in clinical trials, and systematic reviews have not identified a consistent increase in adverse events compared with placebo. Oral Boswellia serrata extracts have been evaluated at formulation-specific doses in clinical trials, including Aflapin®/AprèsFlex® at 100 mg daily for 180 days. Longer-term safety data remain limited. (Refs. 3, 12, 13)
Reported side effects may include:
Nausea
Abdominal discomfort
Heartburn or reflux
Diarrhea
Constipation
Headache
Rash or allergic reaction
Taking Boswellia with food may improve gastrointestinal tolerability.
Potential medication interactions are based mainly on laboratory findings rather than documented interactions in patients. Laboratory studies suggest that Boswellia may affect platelet function (Ref. 18), which contributes to blood clotting, and proteins involved in transporting medications through the body (Ref. 19). Laboratory extracts have also inhibited cytochrome P450 enzymes involved in drug metabolism. (Ref. 20) Whether these effects occur at usual supplemental doses or cause clinically important interactions remains uncertain.
Individuals taking prescription medications should consult a healthcare professional before use.
Safety Considerations
Avoid supplemental doses during pregnancy or breastfeeding because adequate safety data are not available.
Consult a qualified healthcare professional before use if you:
Take anticoagulant or antiplatelet medication
Have a bleeding disorder
Are preparing for surgery or an invasive procedure
Take medications with a narrow therapeutic range
Take multiple prescription medications
Have a history of significant allergic reactions to botanical products
Stop use and seek medical guidance if unusual bleeding, persistent gastrointestinal symptoms, rash, swelling, or difficulty breathing occurs.
Safety in children and safety beyond approximately six months of continuous use have not been adequately established.
Evidence Context
Boswellia has been evaluated in randomized controlled trials and conventional meta-analyses. The evidence is promising but not definitive.
When reviewing the research, several limitations should be considered.
Many studies:
Include fewer than 100 participants
Last only 30–90 days, although some newer trials extend to 180 days
Enroll adults with knee osteoarthritis rather than healthy individuals with occasional joint discomfort
Use different Boswellia species, extracts, doses, combinations, and analytical methods
Rely primarily on participant-reported pain and function scales
Are conducted by, funded by, or otherwise connected to ingredient manufacturers
Do not establish prevention of cartilage loss, delayed joint replacement, or other long-term clinical outcomes
Meta-analyses have reached conflicting overall estimates. Positive pooled results and recent formulation-specific trials support a potential benefit, while other analyses show that conclusions change depending on which formulations, comparators, and time points are included.
This is an area in which extract identity matters unusually strongly. Evidence from Aflapin®/AprèsFlex®, 5-LOXIN®, Boswellin® Super, conventional extracts, and combination products should not be treated as one uniform body of evidence.
Summary
Boswellia is a resin-derived botanical studied primarily for its effects on joint comfort, stiffness, mobility, and physical function. The strongest evidence involves standardized Boswellia serrata extracts in adults with knee osteoarthritis.
Among available forms, Aflapin®/AprèsFlex® 100 mg daily currently has the broadest formulation-specific clinical support, followed by 5-LOXIN® 100–250 mg daily. Generic total-boswellic-acid extracts and phytosome formulations may be reasonable in some settings, but their evidence is less directly transferable or less clinically developed.
Overall, Boswellia is best characterized as a promising, generally well-tolerated joint-support option with limited and still-evolving evidence. It should be used consistently rather than as an acute substitute for an analgesic, and it should not replace established medical evaluation or treatment.
Continue exploring:
For formulation considerations and commercially available product examples:
Boswellia Product Guide
For detailed study summaries and source data:
Boswellia References
Browse additional evidence-informed botanical monographs:
Explore Other Botanicals
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Disclaimer: The information provided by Verus PhytoMed™ is for educational purposes only and is not intended as medical advice. This overview summarizes current research and does not provide individualized treatment recommendations. Always consult your physician before starting any new supplement.
